Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical...
-
Upload
brielle-nobles -
Category
Documents
-
view
215 -
download
1
Transcript of Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical...
![Page 1: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/1.jpg)
Antiplatelet and anticoagulant therapy in stroke prevention
Dr Sepehr ShakibDirector
Clinical PharmacologyRoyal Adelaide Hospital
![Page 2: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/2.jpg)
Topics
• Stroke basics
• Risk calculators
• Lipids and strokes
• Antiplatelets– Clopidogrel– Aspirin + dipyridamole
• Warfarin for AF
![Page 3: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/3.jpg)
What are the different types of strokes?
• Ischemic– Lacunar– Thrombotic– Cardioembolic– Watershed
• Hemorrhagic
![Page 4: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/4.jpg)
Ischemic strokes
• Lacunar:– Occlusion of deep penetrating branches of
arteries– Occlusion caused by microatheroma,
lipohyalinosis, hypertension changes– Most caused by hypertension– Account for 20% of all ischemic strokes
![Page 5: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/5.jpg)
Lacunar stroke
![Page 6: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/6.jpg)
Ischemic strokes
• Cardioembolic– Strokes from other parts of the vascular tree eg
atrial fibrillation, recent MIs, endocarditis, aortic arch etc…
– Some caused by lipid accumulation
• Thrombotic strokes– Due to development of thrombosis and occlusion
of blood vessels supplying brain eg middle cerebral artery
![Page 7: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/7.jpg)
Middle cerebral artery stroke
![Page 8: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/8.jpg)
Hemorrhagic strokes
• Much more rare and more catastrophic
• Caused by:– Hypertension– Amyloid angiopathy– Aneurysms
![Page 9: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/9.jpg)
Hemorrhagic stroke
![Page 10: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/10.jpg)
Hemorrhagic transformation
• Development of hemorrhage in large ischemic stroke
![Page 11: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/11.jpg)
Risk calculators: http://www.cvdcheck.org.au/
![Page 12: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/12.jpg)
Risk
• 52 years old
• Bp 142/87
• Family history of IHD
• LDL 6.4, HDL 0.8
• Has just stopped
smoking
![Page 13: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/13.jpg)
Risk Engine
Based on UKPDS follow-up data
![Page 14: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/14.jpg)
Relationship between lipids and strokes
• BMJ June 2003
![Page 15: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/15.jpg)
Stroke reduction for 1mmol/L reduction in LDL cohort studies
15% reduction in ischemic strokes
19% increase in hemorrhagic strokes
![Page 16: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/16.jpg)
Association between lipids and strokes summary
• As your LDL falls ischemic strokes
– ↑ hemorrhagic strokesOverall benefit depends on the relative balance of
absolute risks of ischemic vs hemorrhagic strokes
• Even with ischemic strokes get smaller relative reduction in events than IHD– Cf 32% (95% CI 27-36%) reduction in ischemic heart
disease events for every 1 mmol/L reduction in LDL
![Page 17: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/17.jpg)
Benefits of lipid lowering in trials
• Original evidence from IHD trials– Eg reduction in strokes in 4S and LIPID study
• Heart Protection Study first study to demonstrate reduction in strokes in those without IHD (Lancet 2002)– 25% reduction in all strokes
![Page 18: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/18.jpg)
Aspirin
• Antithrombotic Trialists’ Collaboration
• BMJ 2002• 287 studies involving
205,000 patients!• Most placebo
controlled data related to aspirin
![Page 19: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/19.jpg)
Relative Benefit
![Page 20: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/20.jpg)
Absolute benefit
![Page 21: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/21.jpg)
Benefits in other vascular events
![Page 22: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/22.jpg)
What about risk of bleeding?
![Page 23: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/23.jpg)
GI bleeding
• Meta-analysis 24 RCTs with 66,000 patients
• 0.45% annual bleeding rate
• OR 1.68 (95% CI 1.51-1.88)
![Page 24: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/24.jpg)
Hemorrhagic stroke risk
• 16 trials, 66542 patients
• 108 hemorrhagic strokes
• Risk 0.05% per year
![Page 25: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/25.jpg)
What about dose of aspirin- efficacy
“There remains uncertainty about such low doses (<75mg) are as effective”
Antiplatelet Trialists Collaboration
![Page 26: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/26.jpg)
Dose of aspirin- toxicity?
• Opinion quite varied from there being no dose dependency to there being one
• No direct comparison of doses
• Small adverse event rate
• Differences in background populations in different studies
![Page 27: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/27.jpg)
Am J Cardiol 2005
• 31 trials
• 192,036 patients
• Looked at low (<100mg), moderate (1-200mg) and high dose (>200)
![Page 28: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/28.jpg)
Bleeding risk
There appears to be dose dependencyToxicity is substantial even at low dose
![Page 29: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/29.jpg)
Aspirin summary
• Effective at reducing rate of recurrent stroke
• Even small doses associated with risk of bleeding– Mainly GI bleeding but some intracerebral
• Benefit outweighs risk in patients with previous stroke
• There appears to be increased toxicity at increased doses
![Page 30: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/30.jpg)
Aspirin Questions?
![Page 31: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/31.jpg)
Clopidogrel
• CAPRIE study
• Clopidogrel 75mg vs aspirin 325mg
• History of stroke, MI, or peripheral vascular disease
• 19,185 patients
![Page 32: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/32.jpg)
Clopidogrel efficacy
5.8%
5.3%
![Page 33: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/33.jpg)
Clopidogrel toxicity
* p<.05
![Page 34: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/34.jpg)
Aspirin + Dipyridamole
• Antithrombotic Trialists Collaboration 2002– 6% non-significant reduction in strokes with
addition of dipyridamole to aspirin– Systematic review of 25 studies, involving
10,404 patients
![Page 35: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/35.jpg)
ESPRIT study
• 2700 patients randomised to any dose of aspirin +dipyridamole SR 200mg twice daily
• Open label
![Page 36: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/36.jpg)
Esprit results
• Fewer strokes with aspirin + dipyridamole
• Fewer hemorrhages with aspirin + dipyridamole (??)
• Systematic review of 6 studies shows reduction in recurrent events
![Page 37: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/37.jpg)
Antiplatelet therapy
Which is the ideal antiplatelet?
• Stroke 2008 meta-analysis: addition of dipyridamole to aspirin: ‘robust benefit’
• Editorial: “…considering the 40 times difference in cost and the discrepancies noted above, such benefit is uncertain and, judging by the data, far from robust”
![Page 38: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/38.jpg)
What about aspirin+dipyridamole compared to clopidogrel?
![Page 39: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/39.jpg)
PROFESS
• Recent ischemic strokes
• Randomised to clopidogrel or asa+dip
• 20,000 patients for 2.5 years
• Non-inferiority design
![Page 40: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/40.jpg)
Primary outcome- recurrent stroke
Hazard Ratio for Aspirin–ERDP 1.01 (0.92–1.11)
![Page 41: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/41.jpg)
Safety outcomes
![Page 42: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/42.jpg)
Other safety
![Page 43: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/43.jpg)
Antithrombotic options
Drug Efficacy Adverse effects
Aspirin 22% in risk Bleeding risk
(0.5-1% per year)
Aspirin + dipyridamole
? more effective than aspirin
Headaches, nausea, flushing
Clopidogrel Slightly more effective than aspirin
Similar bleeding to aspirin
Warfarin Same as aspirin More bleeding
Aspirin + Clopidogrel
Same as aspirin More bleeding
![Page 44: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/44.jpg)
Antiplatelet key messages
• Aspirin is antithrombotic of choice in primary stroke prevention when CV risk is high
• Aspirin, aspirin+dipyridamole or clopidogrel are main antiplatelet cfhoices in secondary stroke prevention– Choice depends on circumstances (PBS
criteria, intolerances)
![Page 45: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/45.jpg)
Antiplatelet questions?
![Page 46: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/46.jpg)
Risk of stroke with AF
• Risk highest with valvular AF
• All other stratification tools refer to non-valvular AF
• There are numerous different risk stratification tools which rely on different risk factors
![Page 47: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/47.jpg)
CHADS2
Score• National Registry
of Atrial Fibrillation
• JAMA 2001
• Subsequently validated in different studies
![Page 48: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/48.jpg)
![Page 49: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/49.jpg)
Benefit of antithrombotic therapy
• Warfarin reduces risk of stroke by 70%
• Aspirin reduces risk by 30%– Less effect on large disabling strokes
• Aspirin + dipyridamole- very limited data
• Clopidogrel- no data
• Aspirin + clopidogrel- not as good as warfarin ? Better than aspirin
![Page 50: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/50.jpg)
Warfarin contraindications
![Page 51: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/51.jpg)
Not contraindications
Co-prescription of interacting drug
![Page 52: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/52.jpg)
What is risk of bleeding with warfarin?
• Literature rate varies between 0.1%-50% per year• Initiation/transition period
– Risk of mis-communication, new behavior– Modifiable risk
• Bleeding due to underlying lesion– Eg colonic polyp, peptic ulcer, bladder lesion– “Desirable” bleeding– Not modifiable
• Long term bleeding risk– Depends on risk factors of bleeding and how well managed– Partly modifiable
![Page 53: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/53.jpg)
5 point risk calculator
• Only applies to patients who are suitable for warfarin
• Validated in other populations
• Am J Med 1998
![Page 54: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/54.jpg)
5 point bleeding scale
• 1 point each for :• Age > 65
• History of stroke
• History of gastrointestinal bleeding
• 1 point for any of: diabetes, recent MI, Hb<10, Creat >.13mmol/L
Score
Classifi-cation
Risk of major bleed
At 1 year
0 Low 3%
1 - 2 Intermediate 12%
3 - 4 High 25%+
![Page 55: Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital.](https://reader036.fdocuments.us/reader036/viewer/2022062620/551ad47655034656628b6283/html5/thumbnails/55.jpg)
Warfarin questions?